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ABSTRACT: High-density lipoprotein (HDL) cholesterol levels are associated with 
decreased risk of atherosclerotic disease, but also not all HDL are functionally equivalent.   
The functional status of HDL is closely linked to its primary protein component, 
apolipoprotein A-1 (ApoA-I) levels and paraoxonase 1 (PON1) enzyme. Functional 
changes of HDL may arise from hyperbaric oxygen therapy (HBO) induced 
posttranslational modification of ApoA-1 and PON1 levels. A total of 41 patients who met 
the research criteria were included in the study. On average, 30 sessions of HBO therapy 
were performed (range: 20-39). Laboratory measurements were performed at the beginning 
and at the end of HBO treatment in two groups of the same patients. We measured serum 
levels of Apo A-1, PON1, oxidized LDL (OxLDL) and routine lipid laboratory parameters 
to determine possible changes in HDL function with HBO therapy. As unexpected, long 
term HBO treatment have no effect on OxLDL and also on PON1 enzyme. However, the 
mean ApoA-1 values in the second group were statistically significantly increased than 
their pre-treatment values (P < 0.003). This preliminary study showed that HBO therapy 
increased the amount of serum ApoA-1. Actually, it can be assumed that the treatment of 
HBO does not have a negative effect on HDL functionality. The increase in ApoA-1 with 
HBO therapy is probably aimed at protecting against oxidative stress in patients. As a 
result, there is a need for larger clinical trials to determine the possible effects of HBO 
therapy on HDL functionality. 
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Hyperbaric oxygen (HBO) therapy serves as the 
primary or secondary treatment for various medical 
conditions. The use of HBO therapy has increased 
significantly over the past decade in various 
diseases1. So how does HBO therapy have a 
common effect in these very different diseases? 
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It has been understood that the combined effect of 
hyperoxia and hyperbaric pressure results in 
improved mitochondrial metabolism, which targets 
both oxygen and anti-oxidative stress genes, leads 
to a significant improvement in tissue oxygenation 
and has anti-apoptotic and anti-atherosclerotic 
effects2. In fact, the use of O2 in basic supra-
physiological pressures has the potential to support 
systemic overproduction of O2 radicals2. HBO 
therapy is also associated with changes in lipid 
metabolism. It is known that the imbalance of free 
radical formation or intensive consumption of 
antioxidant molecules leads to deleterious 
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modification of biological macromolecules such as 
lipids, lipoproteins and enzymes3. 
 
The effect of HBO therapy on HDL functionality is 
unknown. HDL functionality hypothesis suggests 
that measurement of serum HDL levels has no 
major relationship with how the HDL 
concentrations are being dynamically remodeled or 
the state of HDL measurement4. The tremendous 
functional heterogeneity inherent to HDL is driven 
mostly by its compositional heterogeneity.  
However, the majority of HBO patients may have 
HDL dysfunction because diabetes and the 
metabolic syndrome are common in these patients. 
HDL is known to undergo dramatic modification in 
structure and composition as a result of the 
concerted actions of the acute-phase response and 
inflammation. This ‘dysfunctional’ HDL is 
characterized by decreased levels and activities of 
anti-inflammatory and anti-oxidant factors, such as 
ApoA-I and PON15. 
 
Furthermore, transgenic over-expression of ApoA-
1 gene or direct infusion of plasma derived or 
recombinant wild type or mutant ApoA-1 and gene 
transfer of other HDL associated proteins have 
been shown to be athero-protective in limited 
clinical settings, thereby justifying current focus on 
HDL based therapies6. So, HDL inhibits LDL 
oxidation, scavenges toxic phospholipids from 
OxLDL and protects the vascular wall from the 
damaging effects of OxLDL5. 
 
PON1 is a HDL-associated enzyme with potent 
anti-oxidative and atheroprotective effects, having 
the potential to hydrolyze OxLDL-cholesterol. One 
of the anti-oxidative components of HDL is PON1, 
which is synthesized in the liver. The various 
functions of PON1 are: Inhibition of LDL 
oxidation, inhibition of HDL peroxidation, and 
detoxification of homocysteine thiolactone, a pro-
atherogenic compound. Also, serum PON1 activity 
directly correlates with the amount of stearic acid 
and dihomo-gamma- linolenic acid present in 
Apoprotein A-1 and phospholipids in HDL4,7. 
 
Lipoproteins and their alterations are wholly linked 
with increased risk of developing an atherosclerotic 
disease. Loss of ApoA-1 content of HDL is the 
mainstay in the development of atherosclerosis 
with reference to HDL. Hence our attention has to 
shift towards determining the qualitative aspects of 
HDL in order to reduce the risk of atherosclerosis8. 
Furthermore, as far as we know, there have been no 
previous studies showing the functionality of HDL 
in patients receiving HBO therapy. However, a 
number of lipid metabolism changes have been 
observed in many in vitro and animal studies after 
the administration of HBO therapy. 
 
Lipid changes associated with HBO therapy, 
especially focusing on HDL functionality, have not 
yet been identified in humans. In the case of HBO 
therapy, levels of ApoA-1 and PON1 enzyme 
linked to HDL have not been measured yet. The 
measurement of ApoA-1 and PON1 enzyme 
activity along with the routine lipid profile provides 
a simple way to determine the quality of the HDL 
particle. Our aim in this study is to assess the 
possible effect of HBO therapy on HDL associated 
PON1 and ApoA-1 levels in HBO patients. For this 
purpose, we measured serum levels of PON1, 
ApoA-1 and routine laboratory parameters of 




Study population and clinical examinations  
 
In 2017, 41 patients (male, 66.3%) between 20-87 
years of age (mean: 50.7 ± 13.2) who received 
HBO treatment were prospectively included in this 
study for a period of 6 months. All patients had a 
comprehensive physical examination, completed a 
generalized questionnaire and gave informed 
consent before being included in the study. In the 
questionnaire: age, socio-economic status, roots of 
ancestors, physical activity status, history of 
smoking and alcohol consumption and detailed 
medical history were recorded.   
 
Body mass index (BMI) was calculated as weight 
in kilograms divided by height in meters squared. 
Hypertension was defined as systolic blood 
pressure of at least 140 mmHg, diastolic blood 
pressure of at least 90 mmHg according to the 
American Heart Association/American College of 
Cardiology Guidelines. Consequently, blood 
pressure was measured manually with a 
sphygmomanometer in all patients. Initially, the 
inclusion criteria consisted of patients older than 18 
years who had no contraindication to HBO therapy. 
Exclusion criteria included smoking, alcohol 
consumption, current anti-lipid and antioxidant 
treatments. Clinical and laboratory data were 
recorded for all patients. The protocol was 
approved by the Institutional Review Board and 
performed in accordance with the Declaration of 
Helsinki as revised in 2001. Informed consent was 




Every sequential session was conducted five days a 
week with 120 minutes each session. Each 
participant breathed 100% oxygen at 2.5 
atmospheres absolute, with five-minute air break 
periods every 30 minutes, in a multi place 
hyperbaric chamber (Baroks MUL 35®). Each 
HBO treatment session also included 15-minute 
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compression and 10-minute decompression 
periods.  
 
Blood sampling and laboratory measurements 
Blood sample collection 
 
Blood samples were taken from all patients before 
starting HBO therapy, after 12 hours fasting. Blood 
samples were drawn from the peripheral vein 
immediately before the first and after the 20th 
sessions, which represented the minimum duration 
of HBO treatment. Blood samples were obtained 
after an overnight fasting state in the morning. The 
samples were then centrifuged at 3,000 rpm for 15 
minutes, and the serum was stored at -80°C for 
later analysis. Lipid parameters were measured 
immediately. 
 
Routine Laboratory parameters 
 
The levels of triglycerides (TG), total cholesterol 
(TC), HDL-cholesterol (HDL-C) and serum 
creatinine were determined by using commercially 
available assay kits (Abbott) with an auto analyzer 
(Architect® c16000, Abbott Diagnostics). LDL-
cholesterol (LDL-C) levels were calculated from 
Friedewald formula: LDL-C = Total cholesterol – 
HDL – TG/2.2. 
 
Measurement of PON1 and ApoA-1 levels in 
serum  
 
The samples were tested for Human ApoA-1 
(Biont®, Catalog no: YLC0115HU), Human PON1 
(Biont®, Catalog no: YLA0984HU) and Human 
OxLDL (Biont®, Catalog no: YLA0257HU) using 
a sandwich enzyme linked immunosorbent assay, 
according to the manufacturer’s instructions. The 
results were expressed as ng/ml, ng/ml and ng/L, 
respectively.   
 
Statistical analysis of data  
 
Continuous variables were expressed as mean ± 
SD, and categorical variables were presented as 
numbers and percentages. The statistical analysis 
was performed using MedCalc© Statistical 
Software version 15.8 (MedCalc Software® bvba, 
Ostend, Belgium; https://www.medcalc.org; 2018). 
The Kolmogorov-Smirnov test was used to assess 
the distribution of continuous variables, and paired 
samples t-test, chi-squared test, and Wilcoxon 
signed ranks test were used to compare 





The demographic and clinical characteristics of the 
subjects are shown in Table 1. In addition, 29% of 
the patients included in the study were using 
different antihypertensive drugs. The mean BMI 
was 25.3 ± 3.6 kg/m2, and number of sessions 
received ranged from 20-40. 
 
Table 1. Baseline characteristics of patients 
receiving hyperbaric oxygen treatment 
 




Age  50.7 ± 13.2 20-87  
Male gender, n (%)  27 (66)  p*=0.01 
Weight (kg)  76.7 ± 14.0  50-102  
BMI (kg/m2)  25.3 ± 3.6 
kg/m2 
20-37  
Number of sessions 
received  
30  20-40  
Antihypertensive   29%  
*Chi-squared test 
 
Percentage distribution of patients entering HBO 
treatment according to diseases is presented in 
Table 2 and Figure 1. Frequency of distribution of 
the disease; Idiopathic sudden sensorineural 
hearing loss 32%, diabetic foot 25%, avascular 
necrosis 12%, chronic osteomyelitis 11%, 
peripheral vascular disease 9%, Buerger disease 
5% and others 6%. 
 
Table 2. Percent distribution of patients with 
hyperbaric oxygen treatment according to 
diseases 
 
Disease (n=41)  
Idiopathic sudden sensorineural 
hearing loss  
13  
Diabetic foot  10  
Avascular necrosis 5  
Chronic osteomyelitis  4  
Peripheral vascular disease  3  
Buerger's disease  3 
Others (venous ulcer, graft-related 




Post-treatment status of HBO therapy patients is 
given in Table 3. There were no adverse signs 
observed in HBO-treated patients. At baseline prior 
to therapy, serum ApoA-1 levels was mean ± SD 
1.684 (range; 0.791-2.156). Interestingly, there was 
a statistically significant rise in ApoA-1 levels 
during HBO treatment (Table 4). Indeed, second 
group HBO patients serum ApoA-1 values were 
statistically significantly higher than pre-treatment 
ApoA-1 values; 1.913 µg/ml mean ± SD (range; 
1.717-2.109), P<0.038, Figure 1. 
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Table 3. Post-treatment status of hyperbaric 
oxygen treatment patients 
 
Status (n=41)  
Cured  9 
Improved  28 
No Change  4  
 
Table 4: Comparison of the biomarkers of 
patients receiving hyperbaric oxygen therapy at 

























545 ± 29  549 ± 33  0.45  
LDL cholesterol 
(mg/dL) 




39 ± 13  41 ± 12  0.52  
Triglyceride 
(mg/dL)  
213 ± 28  197 ± 15 0.12  
ApoA-1/ 
HDL*** 
0.0431 0.0466 0.05 
*Median (IQR) / Wilcoxon signed ranks test 
**Mean ± SD / Paired samples t-test 
*** Paired samples t-test 
 
 
Figure 1: Serum Apolipoprotein A-1 
concentration distributions of the patients at 
baseline and at the end of Session 20 
 
Whereas, compared to pretreatment values (mean ± 
SD; ng/L), PON1 levels did not change 
significantly after the HBO therapy, P=0.17 Figure 
2. Also, compared to pretreatment values (mean ±S 
D; 545 ± 29 ng/L), OxLDL levels did not change 
significantly after the 20th session (mean ± SD; 
549 ± 33 ng/L), P=0.45, Table 4 and Figure 3. In 
addition, the mean serum lipid levels for both pre- 
and post-HBO treatment are provided in Table 4. 
There were no statistically significant differences in 
all routine lipid parameters after the HBO treatment 
 
 
Figure 2: Serum Paraoxonase-1 concentration 
distributions of the patients at baseline and at 
the end of Session 20 
 
 
Figure 3: Serum Oxidized LDL concentration 
distributions of the patients at baseline and at 




The first result we obtained is that long-term HBO 
therapy may have a positive effect on patients' 
HDL functionality. After HBO therapy, the level of 
ApoA-1 required for normal functionality of HDL 
was significantly increased in all patients. The most 
important finding of this study is, of course, the 
increase in the ApoA-1 level in the serum of 
patients receiving HBO therapy. It should be kept 
in mind that HDL is made up of many proteins, 
lipids and ApoA-1 (for over 70% of the total 
protein mass). So, HDL serves as a prominent anti-
atherogenic function by mediating reverse 
cholesterol transport5,9.  It is the first clinical study 
to show this relationship between	HBO therapy and 
ApoA-1. 
 
Pharmacological treatment of dyslipidemia and 
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prolong the survival of the patient and reduce the 
incidence of cardiovascular events. However, some 
non-pharmacological cholesterol lowering 
interventions such as HBO therapy has not been 
well studied. However, this study shows that HBO 
treatment carries the potential to cause lipid 
metabolic changes in a variety of patients, which 
may reduce atherosclerotic diseases. 
 
In the literature, there is very little research 
showing the effect of HBO therapy on lipoproteins. 
For example, in one study, changed lipoprotein 
subfractionation was demonstrated in diabetic 
patients with HBO therapy. As a result, it has been 
reported that the VLDL and IDL subfractions 
decrease after HBO therapy10. 
 
In addition, several other studies have shown that 
HBO therapy does not cause an increase in OxLDL 
levels11. Similar to these studies, the HBO therapy 
did not make any statistically significant change at 
the level of OxLDL in our study. In the past 
decades, OxLDL has attracted attention as a blood 
marker that is associated with atherosclerosis. The 
oxidative modification of LDL in the artery wall 
has been implicated as one of the major 
physiologically relevant mechanisms for the 
pathogenesis of atherosclerosis11. 
 
Unfortunately, we have not found any studies in the 
literature to evaluate serum ApoA-1 levels and 
PON1 activity with HBO therapy in humans but an 
increase in PON1 level was demonstrated in 
preclinical animal experiments. Evidently, the 
HDL-associated serum PON1 enzyme activity did 
not show an analytical change in our patients as a 
result of HBO therapy. As a result, this study 
suggests that long-term high-pressure oxygen 
therapy may not affect serum PON1 activity. 
 
Although the release of reactive oxygen species 
was recognized as a critical step in combating 
invaders, excessive production of reactive oxygen 
species can trigger oxidative stress that causes 
significant harm to cells. It is well known that 
oxidative stress can lower PON1 activity and 
increase the OxLDL12. At least in our patients the 
oxidative stress on PON1 and OxLDL during HBO 
treatment was not adversely affected. In addition, 
HBO therapy did not alter routine blood lipid 
parameters. 
 
Many studies indicate that the HDL proteome can 
change in a variety of disease states and these 
changes are often related to in vitro measures of 
HDL function. Normal functional HDL has high 
levels of active antioxidant proteins, enzymes with 
high antioxidant potential and has anti-
inflammatory activity. So, HDL can directly inhibit 
oxidation of LDL. PON1 may be interacting with 
ApoA-1 to inhibit LDL oxidation. Anti-atherogenic 
properties of HDL have been largely ascribed to 
ApoA-I, the major protein component of the 
lipoprotein particle. Apo-A1 also manifests anti-
inflammatory and anti-thrombotic activities that 
contribute to HDL's key role in preventing 
atherosclerosis development 4,13. 
 
Recent data show that ApoA-1 concentrations are 
superior to HDL in predicting cardiovascular risk, 
but this approach has not yet been incorporated into 
national guidelines. 
 
Furthermore, novel therapeutic interventions that 
increase ApoA-1 concentrations may be superior to 
those that primarily increase HDL concentrations, 
but this superiority remains largely theoretical at 
present. These results suggest that ApoA-1 
overexpression may reduce oxidative stress by 
decreasing ROS levels in patients8,13. 
 
ApoA-1 mimetics have been shown in animal 
models and humans to have therapeutic potential 
for reversing atherosclerosis. However, still 
nothing is known about the ApoA-1 gene 
expression under oxidative stress in commonly 
used treatments like HBO therapy. This is a critical 
step for the molecular basis of a number of 
therapeutic mechanisms. Because, Apo-A1-
deficient mice exhibit significant progression of 
atherosclerosis, an approximately 5-fold increase 
compared to LDL receptor-deficient mice6,14,15. 
Substantially, HBO therapy though has many 
disadvantages, which require further investigation. 
First, HBO treatment requires special equipment, 
which limits its daily practice for atherosclerotic 
patients. Second, long-term effects of HBO 
treatment, for example harmful oxidative stress on 





In this study, a limited sample set was investigated 
and measurements were recorded over a relatively 
short-term period. Further investigation should be 
carried out with long-term prognostic follow-up of 
the patients. Therefore, the relationship between 
HDL function and HBO therapy should be 
demonstrated by larger clinical trials. This 
preliminary study of patients with HBO therapy 
gives promising results for HDL functionality. In 
the future there will be need for expanded clinical 
trials. In this study, a limited patient group was 
investigated and laboratory measurements were 
recorded over a relatively short-term period. Future 
investigation should be achieved with long-term 
prognostic follow-up of the patients. 
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